Vasant Narasimhan, global head of drug development and chief medical officer for Novartis, said: "SPMS is a particularly disabling form of MS, and there is a need for effective treatment options ...

It is also the first drug approved for patients with primary progressive MS (PPMS), where ... be similar to other highly effective medicines. It will not be the most expensive but it will not ...

Oral fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator, is an effective treatment for relapsing–remitting multiple sclerosis (MS), according ... disease, but most are only ...